CL2024002683A1 - Virus recombinantes de la enfermedad de newcastle y composiciones inmunogénicas para su uso en la prevención del covid-19 - Google Patents

Virus recombinantes de la enfermedad de newcastle y composiciones inmunogénicas para su uso en la prevención del covid-19

Info

Publication number
CL2024002683A1
CL2024002683A1 CL2024002683A CL2024002683A CL2024002683A1 CL 2024002683 A1 CL2024002683 A1 CL 2024002683A1 CL 2024002683 A CL2024002683 A CL 2024002683A CL 2024002683 A CL2024002683 A CL 2024002683A CL 2024002683 A1 CL2024002683 A1 CL 2024002683A1
Authority
CL
Chile
Prior art keywords
protein
immunogenic compositions
covid
prevention
recombinant
Prior art date
Application number
CL2024002683A
Other languages
English (en)
Spanish (es)
Inventor
Palese Peter
Garcia-Sastre Adolfo
Krammer Florian
Sun Weina
Gonzalez Dominguez Irene
Original Assignee
Icahn School Med Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Med Mount Sinai filed Critical Icahn School Med Mount Sinai
Publication of CL2024002683A1 publication Critical patent/CL2024002683A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2024002683A 2022-03-10 2024-09-06 Virus recombinantes de la enfermedad de newcastle y composiciones inmunogénicas para su uso en la prevención del covid-19 CL2024002683A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263318640P 2022-03-10 2022-03-10

Publications (1)

Publication Number Publication Date
CL2024002683A1 true CL2024002683A1 (es) 2025-01-03

Family

ID=87936013

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002683A CL2024002683A1 (es) 2022-03-10 2024-09-06 Virus recombinantes de la enfermedad de newcastle y composiciones inmunogénicas para su uso en la prevención del covid-19

Country Status (11)

Country Link
US (1) US20250186578A1 (enExample)
EP (1) EP4489779A4 (enExample)
JP (1) JP2025509352A (enExample)
KR (1) KR20240161963A (enExample)
CN (1) CN119317446A (enExample)
AU (1) AU2023231285A1 (enExample)
CA (1) CA3245533A1 (enExample)
CL (1) CL2024002683A1 (enExample)
CO (1) CO2024012344A2 (enExample)
MX (1) MX2024011049A (enExample)
WO (1) WO2023173032A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5603012B2 (ja) * 2005-12-02 2014-10-08 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用
WO2021226348A2 (en) * 2020-05-07 2021-11-11 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease virus expressing sars-cov-2 spike protein and uses thereof
EP4408463A4 (en) * 2021-09-30 2026-03-18 Icahn School Med Mount Sinai Recombinant Newcastle Disease Virus Expressing a SARS-CoV-2 Delta Variant Spike Protein and Its Uses

Also Published As

Publication number Publication date
KR20240161963A (ko) 2024-11-13
US20250186578A1 (en) 2025-06-12
EP4489779A2 (en) 2025-01-15
WO2023173032A3 (en) 2023-10-12
MX2024011049A (es) 2024-09-18
WO2023173032A2 (en) 2023-09-14
CN119317446A (zh) 2025-01-14
CA3245533A1 (en) 2023-09-14
JP2025509352A (ja) 2025-04-11
AU2023231285A1 (en) 2024-07-25
CO2024012344A2 (es) 2024-12-30
EP4489779A4 (en) 2026-05-13

Similar Documents

Publication Publication Date Title
US11802273B2 (en) Mutations that confer genetic stability to additional genes in influenza viruses
BR112022022604A2 (pt) Vírus recombinante da doença de newcastle expressando proteína spike sars-cov-2 e seus usos
US11241492B2 (en) Mutations that confer genetic stability to genes in influenza viruses
MX2022015040A (es) Proteina espicular (s) del coronavirus geneticamente manipulada y metodos de uso de la misma.
Nogales et al. Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development
Heaton et al. In vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies
US20210299249A1 (en) Recombinant multivalent influenza viruses
MX2019010275A (es) Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este.
Wirblich et al. Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
CO2024012344A2 (es) Virus de la enfermedad de newcastle recombinantes y composiciones inmunogénicas para su uso en la prevención de la covid-19
CR10064A (es) Virus quimericos que presentan proteinas de superficie no nativas y usos de los mismos
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
MX2021004859A (es) Vacuna de ibv h52 con proteina espicular heterologa.
Luo et al. Two potential recombinant rabies vaccines expressing canine parvovirus virion protein 2 induce immunogenicity to canine parvovirus and rabies virus
WO2023056351A8 (en) Recombinant newcastle disease virus expressing spike protein of sars-cov-2 delta variant and uses thereof
WO2023196759A3 (en) Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant
CU20120057A7 (es) Composición vacunal contra el virus del dengue, kit y plásmido
AR056133A1 (es) Virus de influenza canina y composiciones relacionadas y metodos de uso
CO2023015564A2 (es) Virus quimérico de la enfermedad de newcastle que expresa las proteínas hn y f del apmv
NI201700080A (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas.
AR124522A1 (es) COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEÍNA SPIKE DEL SARS-CoV-2
US11274282B2 (en) Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen
Yamada et al. Lineage-matched Oropouche virus mRNA-LNP vaccines confer complete, cross-protective immunity in mice
AR085800A1 (es) Vacuna de rinitis equina